Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

2023-06-07
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from 14 ordinary shares per ADS to 4000 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-285.714 reverse stock split of the ADSs. The ADSs will continue to trade over-the-counter under a new CUSIP. Forward’s ordinary shares will not be affected by the change, the change will have no effect on the total number of ordinary shares in the ADS program, nor will it affect the total market value of our ADS or the market cap of the Company. The new ADS to ordinary share ratio of 1-for-4000 will be effective on June 8, 2023. No fractional ADSs will be issued. Holders who would otherwise receive fractional ADSs will receive a cash payment in lieu of such fractional ADSs. The cash in lieu rate will be set when the depositary sells the ADSs that would otherwise have been issued as fractional ADSs in one or more market trades. Kindly see additional information at the links to the websites of the Company and its depositary, Bank of New York Mellon below. Forward Pharma A/S Investor Relations Contact: Investor Relations investors@forward-pharma.com
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。